Lowe Brockenbrough & CO Inc Biogen Inc. Transaction History

Lowe Brockenbrough & CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $1,101 - $1,272	-4 Reduced 0.53%	750 $213,000
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $1,026 - $1,169	4 Added 0.53%	754 $209,000
Q3 2022 Nov 01, 2022	BUY	$194.69 - $268.46 $146,017 - $201,344	750 New	750 $200,000
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $167,940 - $215,827	-750 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $182,212 - $213,472	750 New	750 $210,000
Q4 2020 Feb 04, 2021	SELL	$236.26 - $355.63 $177,195 - $266,722	-750 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$220.06 - $304.07 $50,613 - $69,936	-230 Reduced 23.47%	750 $223,000
Q4 2018 Feb 15, 2019	SELL	$278.5 - $352.75 $6,405 - $8,113	-23 Reduced 2.29%	980 $295,000
Q3 2018 Nov 15, 2018	SELL	$293.51 - $383.83 $5,283 - $6,908	-18 Reduced 1.76%	1,003 $354,000
Q3 2017 Nov 07, 2017	BUY	$281.15 - $329.69 $287,054 - $336,613	1,021	1,021 $320,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Lowe Brockenbrough & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Lowe Brockenbrough & CO Inc with notifications on news.